These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8681493)

  • 41. Single dose pharmacodynamics of thioridazine and remoxipride in healthy younger and older volunteers.
    Swift CG; Lee DR; Maskrey VL; Yisak W; Jackson SH; Tiplady B
    J Psychopharmacol; 1999; 13(2):159-65. PubMed ID: 10475722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Iosulamide: human tolerance study of a new intravenous cholangiographic drug.
    Nelson JA; White GL; Nakashima EN
    Invest Radiol; 1980; 15(6):511-6. PubMed ID: 7203907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist.
    Acton G; Broom C
    Br J Clin Pharmacol; 1989 Oct; 28(4):435-41. PubMed ID: 2574051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.
    Liem-Moolenaar M; Peeters P; Kamerling IM; Hogg C; Holder G; Kleijn HJ; Spaans E; Udo De Haes J; de Kam ML; Franson KL; Cohen AF; van Gerven JM
    Br J Clin Pharmacol; 2013 Jun; 75(6):1455-67. PubMed ID: 23116363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose-finding study of oral metopimazine.
    Herrstedt J; Sigsgaard T; Angelo HR; Kampmann JP; Hansen M
    Support Care Cancer; 1997 Jan; 5(1):38-43. PubMed ID: 9010988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced resident time and pharmacodynamic effects of acepromazine after subclinical multiple dosage in exercised thoroughbreds.
    Chou CC; Chen CL; Rice BL; Colahan PT
    J Vet Pharmacol Ther; 2002 Oct; 25(5):379-82. PubMed ID: 12423229
    [No Abstract]   [Full Text] [Related]  

  • 47. The value of assessing cognitive function in drug development.
    Wesnes KA
    Dialogues Clin Neurosci; 2000 Sep; 2(3):183-202. PubMed ID: 22033754
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
    de Visser SJ; van der Post J; Pieters MS; Cohen AF; van Gerven JM
    Br J Clin Pharmacol; 2001 Feb; 51(2):119-32. PubMed ID: 11259983
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biotransformation of post-clozapine antipsychotics: pharmacological implications.
    Caccia S
    Clin Pharmacokinet; 2000 May; 38(5):393-414. PubMed ID: 10843459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The preclinical discovery and development of cariprazine for the treatment of schizophrenia.
    Wesołowska A; Partyka A; Jastrzębska-Więsek M; Kołaczkowski M
    Expert Opin Drug Discov; 2018 Aug; 13(8):779-790. PubMed ID: 29722587
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antipsychotic medication effects on neuropsychological functions.
    Bilder RM; Turkel E; Lipschutz-Broch L; Lieberman JA
    Psychopharmacol Bull; 1992; 28(4):353-66. PubMed ID: 1363583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men.
    Kleinbloesem CH; Jaquet-Müller F; al-Hamdan Y; Baldauf C; Gisclon L; Wesnes K; Curtin CR; Stubbs RJ; Walker SA; Brunner-Ferber F
    Clin Pharmacol Ther; 1996 Jun; 59(6):675-85. PubMed ID: 8681493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
    Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.
    Allain H; Tessier C; Bentué-Ferrer D; Tarral A; Le Breton S; Gandon M; Bouhours P
    Psychopharmacology (Berl); 2003 Feb; 165(4):419-29. PubMed ID: 12459926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.